WO2022150791A3 - Compositions and methods related to il2 receptor binding - Google Patents

Compositions and methods related to il2 receptor binding Download PDF

Info

Publication number
WO2022150791A3
WO2022150791A3 PCT/US2022/012055 US2022012055W WO2022150791A3 WO 2022150791 A3 WO2022150791 A3 WO 2022150791A3 US 2022012055 W US2022012055 W US 2022012055W WO 2022150791 A3 WO2022150791 A3 WO 2022150791A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
receptor binding
methods related
il2rβ
il2rγ
Prior art date
Application number
PCT/US2022/012055
Other languages
French (fr)
Other versions
WO2022150791A2 (en
Inventor
Robert Kastelein
Rene De Waal Malefyt
Deepti ROKKAM
Patrick J. Lupardus
Sandro VIVONA
Original Assignee
Synthekine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/044853 external-priority patent/WO2022032040A1/en
Application filed by Synthekine, Inc. filed Critical Synthekine, Inc.
Publication of WO2022150791A2 publication Critical patent/WO2022150791A2/en
Publication of WO2022150791A3 publication Critical patent/WO2022150791A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are IL2R binding proteins that bind to IL2Rβ and IL2Rγ and comprise an anti-IL2Rβ VHH antibody and an anti-IL2Rγ VHH antibody.
PCT/US2022/012055 2021-01-11 2022-01-11 Compositions and methods related to il2 receptor binding WO2022150791A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163136095P 2021-01-11 2021-01-11
US202163135884P 2021-01-11 2021-01-11
US63/136,095 2021-01-11
US63/135,884 2021-01-11
USPCT/US2021/044853 2021-08-05
PCT/US2021/044853 WO2022032040A1 (en) 2020-08-05 2021-08-05 Il2rb/il2rg synthetic cytokines

Publications (2)

Publication Number Publication Date
WO2022150791A2 WO2022150791A2 (en) 2022-07-14
WO2022150791A3 true WO2022150791A3 (en) 2022-08-18

Family

ID=82358794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/012055 WO2022150791A2 (en) 2021-01-11 2022-01-11 Compositions and methods related to il2 receptor binding

Country Status (1)

Country Link
WO (1) WO2022150791A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022032040A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US20160017387A1 (en) * 2014-07-18 2016-01-21 Industrial Technology Research Institute Genetically modified microorganism for producing long-chain dicarboxylic acid and method of using thereof
US20180362655A1 (en) * 2015-08-06 2018-12-20 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
WO2020135559A1 (en) * 2018-12-26 2020-07-02 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
US20200399382A1 (en) * 2018-02-15 2020-12-24 Argenx Bvba Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r
WO2022032040A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US20160017387A1 (en) * 2014-07-18 2016-01-21 Industrial Technology Research Institute Genetically modified microorganism for producing long-chain dicarboxylic acid and method of using thereof
US20180362655A1 (en) * 2015-08-06 2018-12-20 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies
US20200399382A1 (en) * 2018-02-15 2020-12-24 Argenx Bvba Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
WO2020135559A1 (en) * 2018-12-26 2020-07-02 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
WO2022032040A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines

Also Published As

Publication number Publication date
WO2022150791A2 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
WO2022150788A3 (en) Compositions and methods related to receptor pairing
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
WO2004035603A3 (en) Erythropoietin receptor binding antibodies
ATE550353T1 (en) BINDING OF IL-6 COMPLEXED WITH IL-6RALPHA TO GP130 PREVENTS ANTI-IL-6 ANTIBODIES
EP4025602A4 (en) Antibodies binding tslp and uses thereof
ATE505489T1 (en) TGF-BETA-1 SPECIFIC ANTIBODIES
CR20130153A (en) PROTEINS OF THE UNION TO IL-12 / P40 (Divisional 9599)
DK2215119T3 (en) Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising the same.
WO2005052004A3 (en) Compositions comprising polypeptides
AU2009260320A8 (en) Antibodies to IL-6 and their uses
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
MY163480A (en) Sclerostin binding agents
MX2023001415A (en) Compositions and methods related to il27 receptor binding.
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
EP3788079A4 (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
WO2022150791A3 (en) Compositions and methods related to il2 receptor binding
EP3990497A4 (en) Cd3 antigen binding fragments and compositions comprising same
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
EP4161964A4 (en) Antibodies binding lag3 and uses thereof
WO2007120766A3 (en) Erythropoietin receptor agonists
CY1115295T1 (en) SYNTHESIS FOR PATHOLOGY CONSULTATION WITH MSRV / HERV-W
EP4126938A4 (en) Antibodies binding siglec15 and uses thereof
EP3847196A4 (en) Bispecific antigen binding proteins and uses thereof
EP3930852A4 (en) Antigen binding proteins that bind bcma
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22737316

Country of ref document: EP

Kind code of ref document: A2